Reimbursement Support
Reimbursement Codes and Allowables
Reimbursement Guide
Patient Education
Prostate Diseases
  Prostate Cancer
  Benign Prostatic Hyperplasia (BPH)
  Prostatitis
  Helpful Links
Patient FAQs
Patient Information from Package Insert
Androgen Reduction Graph
Physician Information


  Bayer Global
  Bayer Corporate - USA
general conditions of use
privacy statement
imprint
© 2007 Bayer HealthCare Pharmaceuticals

 
Physician Support
Helpful Links to Additional Prostate Cancer Information		    
     
 

Viadur is indicated in the palliative treatment of advanced prostate cancer. Bayer is not responsible for, and does not endorse, the information found on these links.

Helpful Links To Additional Prostate Cancer Information

To find out more about prostate cancer, visit the following Web sites.

Prostate Cancer Web Sites

American Association for Cancer Research (AACR)
www.aacr.org
e-mail: foti@aacr.org

American Cancer Society
www.cancer.org

American Foundation for Urologic Disease (AFUD)
www.afud.org
e-mail: admin@afud.org

American Institute for Cancer Research
www.aicr.org
e-mail: aicrweb@aicr.org

American Prostate Society
www.ameripros.org

American Society of Clinical Oncology (ASCO)
www.asco.org
e-mail: asco@asco.org

The American Urological Association, Inc.
www.auanet.org

The Association for the Cure of Cancer of the Prostate
www.capcure.org
e-mail: capcure@capcure.org

Cancer Care
www.cancercare.org

Cancer Hope Network
www.cancerhopenetwork.org

Cancer News on the Net
www.cancernews.com

Cancer Research Institute
www.cancerresearch.org
e-mail: info@cancerresearch.org

Cancerfacts.com
www.cancerfacts.com

CaP CURE, Association for the Cure of Cancer of the Prostate
www.capcure.org

The Education Center for the Prostate Cancer Patients (ECPCP)
www.ecpcp.org
e-mail: JL3730@aol.com

Harvard Center for Cancer Prevention
Your Cancer Risk: The Source on Prevention
www.yourcancerrisk.harvard.edu

The Hypertext Guide to Prostate Cancer
www.hypertext.org/
ENGLISH/OVER.html

Man to Man Prostate Cancer Education and Support Program
www.cancer.org

National Cancer Institute
www.nci.nih.gov
e-mail: webmaster@cancer.org

National Prostate Cancer Coalition
www.4npcc.org
e-mail: info@npcc.org

Prostate Cancer Education Council
www.pcaw.com

Prostate Cancer Research and Education Foundation
www.pcref.org

Prostate Cancer Research Institute
www.prostate-cancer.org
e-mail: pcri@prostate-cancer.org

Us Too! International, Inc
www.ustoo.org

  

Prostate Cancer Newsletters
These sites offer the opportunity to receive regular news updates by e-mail.

AUA NEWS
American Urological Association (AUA)
www.auanews.com
e-mail: aua@auanet.org

BioSpace Genepool
BioSpace.com, Inc.
www.biospace.com
e-mail: sales@biospace.com

MedWire Newswise
www.newswise.com
e-mail:
rjohnson@newswise.com

The Prostate Cancer Exchange
The Education Center for Prostate Cancer Patients (ECPCP)
www.ecpcp.org
e-mail: JL3730@aol.com

The Prostate Forum
www.prostateforum.com
e-mail: rmyers@esinet.net

UPDATE
The American Prostate Society
www.ameripros.org
e-mail: webmaster@ameripros.org

Words to Live By
Cancerpage.com
www.cancerpage.com
e-mail: news@cancerpage.com

Viadur is indicated in the palliative treatment of advanced prostate cancer.

  


Printer-Friendly Version

Important Safety Considerations
Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur.

Viadur is contraindicated in women and pediatric patients and was not studied in women or children.

Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression.

The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).

Distributed and Marketed by:
Manufactured by:

Bayer HealthCare Pharmaceuticals
6 West Belt, Wayne, NJ 07470 USA

© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation.

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.